Journals / The European Research Journal / 2019 / Cilt: 5 - Sayı: 4

Cardioprotective effect of vitamin D and melatonin on doxorubicin-induced cardiotoxicity in rat model: an electrocardiographic, scintigraphic and biochemical study

Pages
649–657
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Vitamin D and melatonin treatment prevented all the parameters of DOX-induced cardiotoxicity in rats.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Doxorubicin (DOX) is an antineoplastic drug that is widely used in chemotherapy but its cardiotoxicity is the most important side effect that limits the clinical use of this drug.
📊
Key Findings & Data:Methods: In this study, forty-nine adult male Wistar albino rats (220 ± 15 g) were randomly divided into seven groups (n = 7 each), namely control (CON, n = 7), doxorubicin (DOX, n = 7), melatonin (MEL, n = 7), vitamin D (Vit D, n = 7), doxorubicin plus melatonin (DOX+MEL, n = 7), doxorubicin plus vitamin D (DOX+Vit D, n = 7), and doxorubicin plus melatonin and vitamin D (DOX+MEL+Vit D, n = 7) groups.
💡
Conclusion & Impact:Conclusion: Vitamin D and melatonin treatment prevented all the parameters of DOX-induced cardiotoxicity in rats.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:doxorubicin-induced cardiotoxicty · vitamin D · melatonin

Abstract

Objectives: Doxorubicin (DOX) is an antineoplastic drug that is widely used in chemotherapy but its cardiotoxicity is the most important side effect that limits the clinical use of this drug. We investigated DOX treatment and the effects of vitamin D and melatonin on heart by electrocardiography, scintigraphic and biochemical methods. Methods: In this study, forty-nine adult male Wistar albino rats (220 ± 15 g) were randomly divided into seven groups (n = 7 each), namely control (CON, n = 7), doxorubicin (DOX, n = 7), melatonin (MEL, n = 7), vitamin D (Vit D, n = 7), doxorubicin plus melatonin (DOX+MEL, n = 7), doxorubicin plus vitamin D (DOX+Vit D, n = 7), and doxorubicin plus melatonin and vitamin D (DOX+MEL+Vit D, n = 7) groups. Cardiotoxicity was induced by intraperitoneal injection (i.p.) of DOX (18 mg/kg, i.p.) on the 15th, 16th and 17th days. Rats receiving vitamin D and melatonin treatment in the DOX-induced cardiotoxicity group received vitamin D (60,000 IU/kg, i.p.) were administered in a single dose and melatonin (40 mg/kg/day, i.p.) for 17 days and were injected with (18 mg/kg, i.p.) on doxorubicin 15th, 16th, and 17th days. On the 18th day electrocardiography (ECG), 99mTechnetium pyrophosphate scintigraphy and biochemical parameters were assessed. Results: DOX caused changes in the ECG pattern, a significant decrease in heartbeat (p < 0.01), P wave (p < 0.001) and QRS complex durations (p < 0.001), R wave amplitude (p < 0.001); elevation in ST-segment (p < 0.001) and decrease in QT interval (p < 0,001), and R-R interval durations (p < 0.001); increase in the serum levels of cardiac injury markers (CK, BUN, cardiac troponin T), (p < 0.01), and increased 99mTechnetium pyrophosphate uptake (p < 0.001) as compared to the CON group. MEL, Vit D and MEL+Vit D administration showed a same protective effect against DOX-induced altered ECG pattern. Pre-treatment with MEL, Vit D and MEL+Vit D significantly protected the heart from the toxic effect of DOX, by decreasing the levels of of cardiac injury markers (CK, BUN, cardiac troponin T) (p < 0.001) and decreased the elevated level of 99mTechnetium pyrophosphate uptake (p < 0.001). Conclusion: Vitamin D and melatonin treatment prevented all the parameters of DOX-induced cardiotoxicity in rats.

🔖

Cite This Article

GÜL, S. S., AYGÜN, H. (2019). Cardioprotective effect of vitamin D and melatonin on doxorubicin-induced cardiotoxicity in rat model: an electrocardiographic, scintigraphic and biochemical study. The European Research Journal, Cilt: 5 - Sayı: 4, 649–657. https://ajindex.com/articles/361228

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14
  2. Bilginoğlu A, Aydın D, Ozsoy S, Aygün H. Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats. Turk Kardiyol Dern Ars 2014;42:265-73
  3. Swamy AH, Wangikar U, Koti BC, Thippeswamy AH, Ronad PM, Manjula DV. Cardioprotective effect of ascorbic acid on doxorubicin-induced myocardial toxicity in rats. Indian J Pharmacol 2011;43:507-11
  4. Anjos Ferreira AL, Russell RM, Rocha N, Placido Ladeira MS, Favero Salvadori DM, Oliveira Nascimento MC, et al. Effect of lycopene on doxorubicin-induced cardiotoxicity: an echocardiographic, histological and morphometrical assessment. Basic Clin Pharmacol Toxicol 2007;101:16-24
  5. Xin Y, Zhang S, Gu L, Liu S, Gao H, You Z, et al. Electrocardiographic and biochemical evidence for the cardioprotective effect of antioxidants in acute doxorubicin-induced cardiotoxicity in the beagle dogs. Biol Pharm Bull 2011;34:1523-6
  6. Othman AI, El-Missiry MA, Amer MA, Arafa M. Melatonin controls oxidative stress and modulates iron, ferritin, and transferrin levels in adriamycin treated rats. Life Sci 2008;83:563-8
  7. Ahmed HH, Mannaa F, Elmegeed GA, Doss SH. Cardioprotective activity of melatonin and its novel synthesized derivates on doxorubicin-induced cardiotoxicity. Bioorg Med Chem 2005;13:1847-57
  8. Prufer K, Veenstra TD, Jirikowski GF, Kumar R. Distribution of 1,25- dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. J Chem Immunol 1999;16:135-45
  9. Langub MC, Herman JP, Malluche HH, Koszewski NJ. Evidence of functional vitamin D receptors in rat hippocampus. Neuroscience 2001;104:49-56
  10. Walbert T, Jirikowski GF, Prufer K. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the limbic system. Horm Metab Res 2001;33:525-31
  11. Kunadian V, Ford GA, Bawamia B, Qiu W, Manson JE. Vitamin D deficiency and coronary artery disease: a review of the evidence. Am Heart J 2014;167:283-91
  12. Majumdar V, Prabhakar P, Kulkarni GB, Christopher R. Vitamin D status, hypertension and ischemic stroke: a clinical perspective. J Hum Hypertens 2015;29: 669-74
  13. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012;97:1153-8
  14. Bansal N, Zelnick L, Robinson-Cohen C, Hoofnagle AN, Ix